US Patent Issued to Board of Regents, The University of Texas System on Aug. 25 for "Compounds with anti-tumor activity against cancer cells bearing HER2 exon 19 mutations" (Texas Inventors)

ALEXANDRIA, Va., Aug. 25 -- United States Patent no. 12,714,708, issued on Aug. 25, was assigned to Board of Regents, The University of Texas System (Austin, Texas).

"Compounds with anti-tumor activity against cancer cells bearing HER2 exon 19 mutations" was invented by Jacqulyne Robichaux (Houston) and John V. Heymach (Houston).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure provides methods of treating cancer in a patient determined to have a HER2 exon 19 mutation, such as a point mutation, by administering a third-generation tyrosine kinase inhibitor, such as poziotinib."

The patent was filed on March 27, 2019, under Application No. 17/042,012.

*For further information, including im...